Cormorant Asset Management »

Silence Therapeutics shares owned by Cormorant Asset Management

Quarter-by-quarter ownership of Silence Therapeutics (SLN) shares owned by Cormorant Asset Management from 13F filings

Historical chart of Cormorant Asset Management investment in Silence Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Silence Therapeutics held by Cormorant Asset Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Silence Therapeutics by Cormorant Asset Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $14M 625k 21.60

More positions owned by Cormorant Asset Management

Moonlake Immunotherapeutics Class A Ord (MLTX)
Eyepoint Pharmaceuticals Com New (EYPT)
Arcellx Common Stock (ACLX)
Alpine Immune Sciences (ALPN)
Bridgebio Pharma (BBIO)
Praxis Precision Medicines I Com New (PRAX)
Corbus Pharmaceuticals Hldgs Com New (CRBP)
Tarsus Pharmaceuticals (TARS)
Longboard Pharmaceuticals In (LBPH)
Edgewise Therapeutics (EWTX)
Crinetics Pharmaceuticals In (CRNX)
Biomea Fusion (BMEA)
Korro Bio (KRRO)
Vaxcyte (PCVX)
Autolus Therapeutics Spon Ads (AUTL)

View all positions for Cormorant Asset Management

Top funds holding Silence Therapeutics

Artal Group
Lombard Odier Asset Management
Lombard Odier Asset Management
Redmile Group
Logos Global Management
Frazier Life Sciences Management
Vivo Capital
Nextech Invest
Henderson Group
Cormorant Asset Management
Adage Capital Partners GP
Aquilo Capital Management
Lynx1 Capital Management
5AM Venture Management
Millennium Management

View all funds holding Silence Therapeutics